Sellas Life Sciences’ zanubrutinib combination shows efficacy in DLBCL
Sellas Life Sciences (SLS) announced data from Phase 2a trial of SLS009 – tambiciclib -, a highly selective CDK9 inhibitor, in ...
SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial
SELLAS Life Sciences Group (NASDAQ:SLS) announced on Thursday promising mid-stage trial results for SLS009, a highly ...
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in ...
Healio3d
Regimen may become new standard for relapsed/refractory diffuse large B-cell lymphoma
The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...
Hosted on MSN13d
MSD commences Phase III trial of DLBCL treatment
MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...
Pharm Exec6d
FDA Approves Pfizer’s Adcetris for Relapsed or Refractory Large B-Cell Lymphoma
Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...
pharmaphorum13d
MSD starts pivotal trial of ROR1 drug in first-line lymphoma
MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...
emjreviews.com2d
New Therapy Hope for Hard-to-Treat DLBCL
Epcoritamab combined with GemOx shows deep, durable responses in transplant-ineligible relapsed/refractory diffuse large ...
Pharm Exec14d
Merck Launches Phase III Trial Evaluating Zilovertamab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...
BioSpace7d
Pfizer Continues Cancer Rally as Adectris Label Expands to Non-Hodgkin Lymphomas
Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental ...
Pharmabiz6d
Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma
Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...